Rationale: Extracorporeal membrane oxygenation (ECMO) has supported gas exchange in children with severe respiratory failure for more than 40 years, without ECMO efficacy studies.
Since the 1970s, extracorporeal membrane oxygenation (ECMO) support has been used to support gas exchange for children with severe acute respiratory failure who fail mechanical ventilation (1) . Currently, approximately 1,500 U.S. children and 3,000 children worldwide receive ECMO support each year (2, 3) . For comparison, this is similar to the annual number of pediatric bone marrow transplants (1, 816) and the combined annual total of pediatric liver, heart, and kidney transplants (1, 758) in the United States (4) (5) (6) (7) . ECMO, with a median hospitalization cost of $230,000, is more expensive than each of these other procedures (7) .
Since 1974, eight randomized controlled trials have been reported in ECMO for respiratory failure, and none have included nonneonatal pediatric patients (8) (9) (10) (11) (12) (13) (14) (15) . Cochrane systematic reviews of this evidence concluded that ECMO for neonatal respiratory failure had a survival advantage (16) , but there was insufficient evidence to demonstrate a survival advantage for ECMO used to support respiratory failure in adults (17) . Moreover, these trials were performed before 2009; since then, advances in ECMO technology have enhanced the delivery of ECMO support (18, 19) , and new research has changed conventional management of severe acute respiratory distress syndrome (ARDS) (20) (21) (22) (23) .
ECMO is now an established, prevalent, and expensive life-support technology, with no nonneonatal pediatric trials and conflicting neonatal and adult evidence (2, 16, 17, 24) . The prospectively collected, high-quality data from the multicenter randomized controlled trial RESTORE (Randomized Evaluation of Sedation Titration for Respiratory Failure) offers a compelling opportunity to address this evidence gap (25) . The primary aim of our reexamination of the RESTORE study data is to determine if pediatric ECMOsupported patients have a lower in-hospital mortality rate than a pair-matched cohort of non-ECMO-supported pediatric patients with ARDS. Our secondary aims are to compare hospital-, pediatric ICU (PICU)-, and ventilator-free days as well as the change in overall and cerebral functional status at hospital discharge.
Methods
This is a pair-matched cohort study using data from the multicenter randomized controlled RESTORE clinical trial, performed from 2009 to 2013 at 31 U.S. PICUs (25) . RESTORE enrolled 2,449 children, aged 2 weeks to 17 years, who were receiving invasive mechanical ventilator support for acute respiratory failure. Each participating institution obtained institutional review board approval and informed consent from the legal guardian of participating patients. Patients were cluster randomized by the PICU to receive usual care or protocolized targeted sedation, with a primary endpoint of mechanical ventilation duration and secondary outcomes including overall functional status, cerebral functional status, and in-hospital mortality. The decision to place a patient on ECMO and the ECMO care delivery during ECMO support was at the discretion of the treating medical team, as was the nonsedation care delivery among non-ECMO-supported patients (25, 26) . Because respiratory supportive care was not protocolized in the RESTORE study, there was likely variability in respiratory care within the ECMO-supported and within the non-ECMO-supported groups. The study protocol and findings have been described elsewhere (25) .
The RESTORE clinical trial database contains admission diagnosis and Pediatric Risk of Mortality from the first 12 hours in the PICU (PRISM III-12) scores, daily assessments of study patients' mechanical respiratory support, mean airway pressure, FI O 2 , Pa O 2 (if arterial specimen available), pulse oximeter-measured oxyhemoglobin saturation, and organ dysfunction scores. In ECMO-supported patients, these same measures were also recorded within 6 hours before the start of ECMO support, as was the ECMO cannulation strategy (venoarterial or venovenous), the type of membrane oxygenator and mechanical blood pump, and the ECMO blood flow rates. We imputed oxygenation index (OI) data in children who were urgently cannulated for ECMO support and missing OI.
OI ¼ ðFi O2 3 mean airway pressure ½cm H 2 OÞ Pa O2 ½mm Hg 3 100
Patient Selection
In the current study, patients were eligible to be considered in the ECMO-supported patient group if the patient received ECMO support within 15 days from the start of mechanical ventilation (27) . Among non-ECMO-supported patients, we excluded patients not considered to be ECMO candidates. This included patients who had received bone marrow transplantation and patients in a vegetative state or in a coma at admission, as measured by Pediatric Overall Performance Category (POPC) of 5 or greater (28) . Remaining non-ECMOsupported patients were eligible for matching at any time during the first 15 days of mechanical ventilation. To be eligible, on the day of matching, non-ECMO-supported patients needed to be mechanically ventilated, on an FI O 2 of at least 0.60, and meet Pediatric Acute Lung Injury Consensus Conference guidelines for severe pediatric ARDS (PARDS) oxygenation criteria (OI >16) (29) .
Outcome
The primary outcome was 90-day inhospital mortality. Secondary outcomes included 90-day hospital-free days, PICUfree days, and ventilator-free days. Pediatric Cerebral Performance Category (PCPC) from admission to discharge (28) . In RESTORE, two-thirds of surviving children were randomly sampled for a 6-month telephone follow-up after hospital discharge. Among sampled patients, we assessed their need for home oxygen and hospital readmission within 6 months after hospital discharge.
Statistical Analysis
Before matching, characteristics of ECMOsupported and eligible non-ECMOsupported patients were compared using generalized estimating equations accounting for PICU as a cluster variable. Then, pair-matched cohort analyses were performed using individual case matching and propensity score matching on the basis of variables expected to be associated with the use of ECMO, similar to previously published studies (30, 31) . In both approaches, 1:1 matching without replacement was made on a daily observation basis. ECMO-supported subjects contributed a single observation on their first ECMO day; non-ECMOsupported subjects could have multiple eligible days for matching, and each patient-day combination was considered separately. Comparisons of characteristics and outcomes of matched pairs after matching were based on exact sign tests and exact 95% confidence intervals for the median of the paired differences for continuous and ordinal variables and exact conditional maximum likelihood estimation for binary variables.
For individual case matching, ECMOsupported patients were matched with non-ECMO-supported patients according to OI group (,20.0, 20.0-29.9, 30.0-39.9, or >40.0), days of mechanical ventilation (62 d), primary diagnosis group (aspiration pneumonia, bronchiolitis, or asthma; pneumonia; sepsis; or other), and age category at PICU admission (2 wk-1.99 yr, 2.00-5.99 yr, or 6.00-17.99 yr). When multiple non-ECMO-supported observations could be matched to an ECMO-supported observation, the non-ECMO-supported observation with the closest OI value and days of mechanical ventilation was selected as the best match.
For propensity score matching, multivariable logistic regression was used to estimate the probability of receiving ECMO treatment for each observation (patient-day). Covariates included continuous OI, days of mechanical ventilation, primary diagnosis group, continuous age in years at PICU admission, number of organ dysfunctions on Day 0 or 1, dichotomized FI O 2 (,100% or 100%), and prior use of high-frequency oscillatory ventilation (HFOV). OI and days of mechanical ventilation were modeled via generalized additive model terms because of nonlinear effects. Each ECMO-supported observation was matched with a non-ECMOsupported observation with the smallest absolute difference in the propensity scores (fitted probabilities).
Additional sensitivity analyses were conducted to confirm whether extreme or imputed OI values affected our findings. For this, we restricted the analysis to ECMOsupported observations whose OI calculation did not involve imputation and was greater than 15, and non-ECMO-supported observations with OI less than 109. Statistical analyses were performed with SAS software, version 9.4 (SAS Institute Inc.) using twosided a = 0.05 level tests.
Results

Sixty-one patients received ECMO at 21 of 31 RESTORE participating PICUs (68%).
No ECMO-supported patients were excluded from the analysis, because all were placed on ECMO by Day 15. Among the 21 RESTORE centers that performed ECMO, their total annual ECMO volumes ranged from 2 to 77 and were greater than 10 at 18 of 21 centers (86%). The ECMO cannulation strategy was venovenous in 38 of 61 cases (62%). Of the 2,388 non-ECMO-supported children, 879 (36.8%) met inclusion criteria, 121 (13.8%) of whom were cared for at one of 10 PICUs (32%) that did not place any RESTORE patients on ECMO ( Figure 1 ).
Before matching, there were no differences between ECMO-supported and non-ECMO-supported patients in age, primary diagnoses, and past medical histories (Table 1) . ECMO-supported children were more often girls, had better baseline POPC and PCPC, higher admission risk of mortality, more organ systems in failure, and higher use of HFOV.
The individual case-matching technique produced 60 matched pairs, and the propensity score-matching technique produced 61 matched pairs. After matching, covariate balance was improved for matched variables (Table 2) . ECMO-supported children had slightly longer length of mechanical ventilation and were more likely to have FI O 2 of 100% on the day of matching than individual case-matched children. Propensity score matching resulted in wellbalanced covariates for all matched variables.
Outcomes
The 90-day hospital mortality rate for individual case-matched patients was 25% for both ECMO-supported and non-ECMO-supported patients (P . 0.99). In propensity score-matched children, the hospital mortality rate was 25% for ECMOsupported versus 30% for non-ECMOsupported patients (P = 0.70) ( Table 3 ).
In the individual case-and propensity score-matched patients, 90-day hospital-, PICU-, and ventilator-free days were also not different from the ECMO-supported patients (Table 3 ). In the propensity score-matched patients, 90-day hospitalfree days were 35 days (interquartile range Among survivors in the individual case-and propensity score-matched patients, the changes from baseline to discharge POPC and PCPC were not different between ECMO-and non-ECMOsupported groups (Table 3) .
At the 6-month telephone follow-up, 21 of the 46 surviving ECMO-supported children and 19 of the 43 surviving non-ECMO-supported propensity score-matched children participated in the follow-up. Two (9%) ECMO-supported and three (16%) non-ECMO-supported children had a new home oxygen requirement after hospital discharge. Nine (43%) ECMO-supported and eight (42%) non-ECMO-supported children had required at least one hospitalization within 6 months after discharge.
After excluding eight cases with imputed data, 53 ECMO-supported patients were available for matching in the sensitivity analyses. Individual case matching yielded 52 matches and propensity score yielded 53 matches, with similar balancing of covariates (see Table E1 in the online supplement) and similar primary and secondary outcomes (Table E2) .
Discussion
In this cohort study of 122 matched children with severe acute respiratory failure supported with and without ECMO, we found no difference in the in-hospital mortality, no difference in the change in overall or cerebral functional status, and no difference in hospital-, PICU-, or ventilatorfree days. To our knowledge, this is the first study in pediatric acute respiratory failure to compare the change in functional outcomes among a matched cohort of ECMOsupported and non-ECMO-supported patients. Our findings were consistent across two separate matching techniques and were robust to a priori sensitivity analysis that restricted data to those without imputed covariates.
There are no clinical trials comparing ECMO support to conventional mechanical ventilation support in PARDS (32) . Our study attempts to address the gap in ECMO efficacy research by reanalyzing the rigorously collected data from the RESTORE clinical trial. The 879 non-ECMO-supported children with severe ARDS offered a large sample to make wellbalanced matches without replacement (30) . We applied these reliable and detailed data to match patients with similar severity of respiratory failure and at similar time points in the course of their illness in a design similar to the approach taken in a study of adult patients (31) .
For a matched cohort study among ECMO-supported patients and non-ECMO-supported patients to be feasible, it needs to be plausible that a similar patient might be placed on ECMO by one provider and not by another. In our study, there is sufficient variability between and within centers in patient selection for ECMO to enable this comparison. First, 121 patients were treated at hospitals that did not offer ECMO. Consequently, those patients were less likely to receive ECMO support for severe acute respiratory failure. Second, among ECMO-supported children, the OI at ECMO initiation, use of HFOV, and days of mechanical ventilation varied greatly, which suggests clinicians have different thresholds for deciding to provide ECMO support. Third, a recently published survey found no consensus on which patients were ECMO candidates (33) . One significant limitation to our findings is power. With only 61 patients receiving ECMO, we are not adequately powered to detect small differences in mortality that would be considered clinically significant. In the primary propensity score-matched analysis we found a 5% lower mortality rate in ECMO-supported patients, and in the sensitivity propensity score-matched analysis there was a 10% lower in-hospital mortality for ECMOsupported patients, but in both cases this difference was not statistically significant. 
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There was variability in ECMO and ventilation practices among all patients in the RESTORE trial (26, 35) . At present, there are no evidence-based guidelines for ECMO support in pediatric respiratory failure (19, 36) . At the time the RESTORE trial was conducted, there were no consensus guidelines or adequately powered pediatric clinical trials in PARDS that identified best practices for mechanical ventilator support in PARDS (29, 37) . This variability in practice can be a symptom of the lack of evidence guiding practice (38) .
The 61 patients receiving ECMO cared for in this study had a similar pre-ECMO severity of illness to patients reported in the Extracorporeal Life Support Organization (ELSO) Registry between 2009 and 2014 (39) . In the ELSO Registry, patients were placed on ECMO at an OI of 44 (IQR, 30-60) and after 2.0 days (IQR, 0.6-6.2 d) of mechanical ventilation, which is similar to the findings in this study (Table 2) (39) . There was also a similar pre-ECMO use of HFOV (44% in ELSO vs. 55% in this study) (39) .
Regarding length of clinical care, the hospital-, PICU-, and ventilator-free days are not statistically different between ECMO-supported and non-ECMOsupported children. However, in a post hoc analysis, when the analysis is restricted to survivors, the PICU and hospital length of stay are significantly longer for the ECMOsupported compared with non-ECMOsupported children. In the a priori specified comparison among propensity scorematched patients, 90-day hospital-free days was 35 days (IQR, 0-59 d) for the ECMO-supported versus 54 days (0-72 d) for the non-ECMO-supported patients (P = 0.06). The absence of a difference between ECMO-supported and non-ECMO-supported patients may reflect a true absence in difference, insufficient power, or a limitation of our model to adjust for underlying differences in the two groups. Notably, the CESAR (Conventional Ventilation or ECMO for Severe Adult Respiratory Failure) trial found that adults randomized to be referred to an ECMO center had a longer ICU and hospital length of stay (14) . Alternatively, a trial randomizing adults to receive pumpless arteriovenous extracorporeal CO 2 elimination versus a strategy of low tidal volume conventional mechanical ventilation (z6 ml/kg) without arteriovenous extracorporeal CO 2 elimination did not replicate these differences (15) .
In our secondary analysis of data from the RESTORE clinical trial, we found a 25% mortality rate in ECMO-supported patients with acute respiratory failure compared with a 40% mortality rate for a similar cohort in the ELSO Registry (39) . It is also lower than the reported mortality for severe ARDS with an OI greater than twenty (43-56%) (40) . Lower mortality rates have also been reported in adult randomized controlled trials of ARDS compared with observational studies. The lower mortality rate in randomized controlled trials is believed to stem from specialized center care, scrutiny of care, and exclusion of patients with poor prognosis (41) . The lower mortality rate may also reflect uncaptured mortality after 90 days but before hospital discharge (42) .
We found no difference between ECMO-supported and non-ECMOsupported patients in the change in functional outcomes. By contrast, the neonatal randomized controlled trial on ECMO versus conventional management showed improved rates of cognitively intact survival among the ECMOsupported group (11) . In our study, we considered the change in neurocognitive status among survivors using the somewhat broad categories of the PCPC, which is slightly different and may partially account for the different finding. Alternatively, some have hypothesized that ECMO may result in worse neurocognitive survival, but our study results do not support that hypothesis for ECMO-supported children with acute respiratory failure (43) .
After the publication of the new PARDS operational definition and practice guidelines as well as the success of several large clinical trials in pediatric critical care, the field is poised to conduct a randomized controlled trial of ECMO versus ventilation therapy alone using patient-level randomization (25, 29, 44, 45) . In such a trial, we would recommend enrolling patients who developed severe PARDS (OI .16) within 48 hours of intubation to ensure patients in both arms receive similar protocolized mechanical ventilation (46) . However, patients would only be randomized to ECMO or continued conventional management once they sustained an oxygenation index of 40 or greater for at least 4 hours (11). Limiting patient enrollment to children who develop PARDS in the first 48 hours seems plausible, because 802 patients enrolled in the clinical trial RESTORE had severe PARDS within 24 hours of study enrollment (25) . In the absence of equipoise, an alternative approach would be to randomize patients to early versus delayed ECMO on the basis of OI thresholds. This study design has been done in early versus delayed renal replacement therapy and in a pilot study among neonates receiving ECMO for respiratory failure (47, 48) .
This study leverages reliably collected data, a large cohort of patients with ARDS, and rigorous statistical technique to compare outcomes among ECMOsupported and non-ECMO-supported patient populations. We did not find a difference in patient outcomes. In the past, it has been proposed that a study of ECMO is unethical, because children who would have survived with ECMO will die without it (49, 50) . This study challenges that notion, and we urge a careful consideration of the best way to perform ethical rigorous research aimed at identifying the best way to support children with severe acute respiratory failure.
Conclusions
In children with severe ARDS, our results do not demonstrate that ECMO-supported children have superior outcomes compared with non-ECMO-supported children. A rigorously performed, randomized controlled clinical trial of ECMO in severe PARDS should be performed to provide definitive answers to this long-standing conundrum in pediatric critical care. n
